Spago Nanomedical's phase I/IIa study Tumorad-01 has met its primary endpoint of identifying the maximum tolerated dose, marking a clinical milestone for the company. In addition to the safety data, new observations of tumour uptake in head and neck cancer patients provide further proof-of-concept for the candidate 177Lu-SN201. These results provide a solid foundation for the upcoming transition into phase II. BioStock reached out to CEO Mats Hansen for a comment.
Read the full interview at biostock.se:
Spago Nanomedical reaches primary endpoint in Tumorad-01
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/